MASLD/MASH Learning Center
Journal Club: Review of Focused Recommendations for the Management of MASLD
September 2026
Thank you to Madrigal for your support on this Journal Club Review video module. This journal club review explores the 2025 focused recommendations for the management of metabolic dysfunction–associated steatohepatitis (MASH) developed by advanced practice providers (APPs) across the United States and published in the Journal of Clinical Gastroenterology. Brian Lam, PA-C, reviews the evolving role of APPs in MASH care, key epidemiology insights, risk stratification using non-invasive tests, and practical guidance on identifying and treating at-risk patients with F2–F3 fibrosis. The discussion highlights real-world use of ELF, FibroScan, and FIB-4, an overview of resmetirom therapy, monitoring strategies, and a look ahead at emerging therapies shaping the future of MASH management. Please visit GHAPP.org, the GHAPP Digital Hub, or the GHAPP ACE 2.0 app for additional resources.
Watch Now
Integrated Transcriptomic and Metabolomic Analyses Reveal the Protective Mechanism of Icaritin Against High-Fat Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice
February 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease. Icaritin (ICT) has demonstrated potential hepatoprotective effects, while its protective mechanisms on MASLD are still unclear. This study aims to investigate the therapeutic efficacy of ICT against MASLD and elucidate its underlying molecular mechanisms. A MASLD mouse model was established via a high-fat diet (HFD) for 12 weeks, with or without gavage of ICT for 4 weeks. Palmitic acid (PA) was...
Read More
Hic-5 promotes the progression of nonalcoholic steatohepatitis by regulating hepatocellular fatty acid metabolism through the PTEN/PGE2/EP4 axis
February 2026
Nonalcoholic steatohepatitis (NASH) is a metabolic disease characterized by hepatic steatosis and inflammation among other features. Dysregulated lipid metabolism is crucial in the pathogenesis of NASH. However, its regulatory mechanisms remain intricate and poorly elucidated. Hepatic stellate cells (HSCs) have been reported to contribute to hepatocellular lipid metabolism dysregulation and aggravate NASH progression. However, the potential mechanisms remain unclear. Here, we demonstrate that...
Read More
Effects of Dietary Adjustment and Fish Oil on Lipid Metabolism, Inflammation, and Serum LPS in Non-Alcoholic Fatty Liver Disease
February 2026
We compared the therapeutic effects of dietary adjustment and fish oil in rats with experimental non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. The NAFLD rats were either maintained on high-fat diet, or transferred from high-fat diet to normal diet, or received a diet with lard replaced with fish oil. Control rats received normal diet throughout the experiment. The liver coefficient, blood lipids, activities of transaminases, and the severity of hepatic steatosis in NAFLD...
Read More
Beyond Organ Boundaries: Molecular Mechanisms of Hepatic Encephalopathy and Parkinson's Disease from the Perspective of the Gut-Liver-Brain Axis
February 2026
Hepatic encephalopathy (HE), a severe neurological complication of liver dysfunction, has long been regarded as a clinical issue confined to liver disease. However, recent clinical observations and basic research have revealed complex pathophysiological connections between HE and Parkinson's disease (PD), 2 seemingly independent conditions. Patients with HE often exhibit irreversible extrapyramidal symptoms that closely resemble the motor disorders of PD; meanwhile, epidemiological studies...
Read More
EMMPRIN deficiency alleviated metabolic-associated steatohepatitis progression via regulation of the UBA52-MCT1 axis
February 2026
CONCLUSION: Our findings demonstrate that EMMPRIN promotes MASH progression through the UBA52-MCT1 regulatory axis, which modulated ubiquitin-dependent protein stability and induced metabolic reprogramming, thereby driving lipid accumulation, inflammation, and fibrosis. These results position EMMPRIN as a promising therapeutic target for MASH intervention.
Read More
LOX-1 gene knockout improves metabolic dysfunction-associated steatohepatitis in mice
February 2026
CONCLUSIONS: LOX-1 gene knockout ameliorates Western diet-induced MASH in mice and may serve as a potential therapeutic target.
Read More
Clinical utility of a 50% and 30% decline in MRI-PDFF in predicting fibrosis improvement in metabolic dysfunction-associated steatohepatitis
February 2026
CONCLUSION: MRI-PDFF super-response predicts fibrosis regression without worsening MASH, and a greater likelihood of MASH resolution without worsening fibrosis than MRI-PDFF response.
Read More
Self-assembled PEGylated nanoparticles based on Elafibranor derivative 3d for the treatment of metabolic dysfunction-associated steatohepatitis
February 2026
No abstract
Read More
Energy metabolism alteration and gene expression reprogramming in a cell model of high fat load non-alcoholic fatty liver disease
February 2026
No abstract
Read More
The Association between NHHR and Nonalcoholic Fatty Liver Disease: Result from NHANES 2017 - 2023
February 2026
CONCLUSIONS: NHHR is strongly linked to an increased risk of NAFLD, suggesting that improving NHHR levels may help mitigate hepatic steatosis.
Read More
Clinical biomarkers and biosensors for early detection of metabolic dysfunction-associated steatohepatitis (MASH): a translational perspective
February 2026
Nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) is a long-term chronic liver disease condition that stems from nonalcoholic fatty liver disease (NAFLD) and results from multiple factors, including lifestyle, metabolic dysfunction, and genetic predisposition. The increasing prevalence of NAFLD in the global population is expected to reach over 35% by 2030. It thus has become a significant public health concern because of its association with...
Read More